Satellos Reports Q1 2026 Financial Results and Clinical Progress
Satellos Bioscience Inc. announced its financial results and corporate highlights for the first quarter ended March 31, 2026. The clinical-stage biotechnology company reported cash reserves of $69.9 million, providing operational runway through 2027 following a $57 million equity offering. Key clinical advancements include the BASECAMP Phase 2 pediatric study for Duchenne muscular dystrophy (DMD), which has eleven active sites and remains on track to complete enrollment by Q3 2026. Additionally, Satellos initiated the TRAILHEAD Phase 2 study in the U.S. for adults aged 16-25 with DMD. Financially, the company recorded a net loss of $9.8 million, an increase from the previous year due to higher research and development expenses linked to clinical trials and increased general administrative costs associated with its Nasdaq listing. CEO Frank Gleeson emphasized the productive quarter, highlighting successful fundraising, the uplisting to Nasdaq, and significant progress in patient screening and site activation for both major studies. The company continues to develop SAT-3247, an oral small-molecule therapy aimed at enhancing muscle regeneration in degenerative muscle diseases.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection